Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zirconium silicate - ZS Pharma

Drug Profile

Zirconium silicate - ZS Pharma

Alternative Names: LOKELMA; Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZS Pharma
  • Developer AstraZeneca; ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia
  • Phase III Kidney disorders

Most Recent Events

  • 01 Dec 2023 Discontinued - Phase-III for Hyperkalaemia (Adjunctive treatment) in USA, Argentina, Brazil, Bulgaria, Canada, China, India, Japan, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand, Turkey, Ukraine, Vietnam (PO) (NCT05056727) (AstraZeneca pipeline, February 2024)
  • 01 Dec 2023 AstraZeneca terminates a phase III DIALIZE-Outcomes trial for Hyperkalaemia (In adults, In elderly) in Argentina, Austria, Brazil, Bulgaria, Canada, China, Czech Republic, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Peru, Poland, Russia, Slovakia, Spain, Thailand, Turkey, Ukraine, United Kingdom, Vietnam, USA and Taiwan (PO, Suspension) (NCT04847232)
  • 17 Nov 2022 AstraZeneca terminates the phase III NEUTRALIZE trial in Hyperkalaemia and Metabolic acidosis associated with Chronic kidney disease (PO) due to a higher than expected screen fail rate (NCT04727528)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top